Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1
- PMID: 37773074
- DOI: 10.1097/PAS.0000000000002131
Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1
Abstract
Activating mutations in MAP2K1 can be seen in benign and intermediate-grade melanocytic neoplasms with spitzoid morphology. We analyzed the clinical, histopathologic, and genetic features for 16 cases of benign and intermediate-grade melanocytic tumors harboring activating MAP2K1 mutations. We compared them to Spitz neoplasms with characteristic Spitz fusions or HRAS mutation. We also compared the mutational pattern of benign and intermediate-grade MAP2K1 -mutated neoplasms and melanomas with activating MAP2K1 mutations. Among the 16 cases, the favored morphologic diagnosis was Spitz nevus (8/16), atypical Spitz tumors (6/16), and deep penetrating nevus (2/16). The 2 most common architectural patterns seen included a plaque-like silhouette with fibroplasia around the rete reminiscent of a dysplastic nevus (n=7) or a wedge-shaped or nodular pattern with the plexiform arrangement of the nests aggregating around the adnexa or neurovascular bundle (n=8). The cases with dysplastic architecture and spitzoid cytology resembled dysplastic Spitz nevi. Compared with true Spitz neoplasms, MAP2K1 -mutated neoplasms occurred in older age groups and had more frequent pagetosis and a lower average mitotic count. The most common type of mutation in the benign and intermediate-grade cases in the literature involves an in-frame deletion, while, in melanomas, missense mutations are predominant. Benign and intermediate-grade melanocytic neoplasms with activating mutations in MAP2K1 can have morphologic overlap with Spitz neoplasms. A significant proportion of melanomas also have activating MAP2K1 mutations. In-frame deletions are predominantly seen in the benign and intermediate-grade cases, and missense mutations are predominantly seen in melanomas.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest and Source of Funding: Supported by the IDP Foundation. P.G. has served as a consultant for Castle Biosciences and has received an honorarium for this; he has also received royalties for textbooks from Elsevier. For the remaining authors none were declared.
References
-
- Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
-
- Hagstrom M, Fumero-Velázquez M, Dhillon S, et al. An update on genomic aberrations in Spitz naevi and tumours. Pathology. 2023;55:196–205.
-
- Benton S, Zhao J, Zhang B, et al. Impact of next-generation sequencing on interobserver agreement and diagnosis of spitzoid neoplasms. Am J Surg Pathol. 2021;45:1597–1605.
-
- Quan VL, Zhang B, Zhang Y, et al. Integrating next-generation sequencing with morphology improves prognostic and biologic classification of spitz neoplasms. J Invest Dermatol. 2020;140:1599–1608.
-
- Sunshine JC, Kim D, Zhang B, et al. Melanocytic neoplasms With MAP2K1 in frame deletions and spitz morphology. Am J Dermatopathol. 2020;42:923–931.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous